A Comparison of Web-Prolonged Exposure (Web-PE) and Present-Centered Therapy (PCT) for PTSD Among Active-Duty Military Personnel

Background: It is urgent to make EBTs for military personnel readily accessible in order to
meet the growing demand for effective and efficient treatment for PTSD in a timely manner.
Effective EBTs for PTSD are available, but barriers to accessing care can deter military
personnel from accessing care. Web-treatments represent an innovative way to overcome these
barriers. The efficacy of previously developed web-treatments for PTSD appear promising,
however, they are not based on treatment protocols with strong empirical support for their
efficacy. Hence, it cannot be discerned whether the outcomes associated with existing
web-treatments are due to the new intervention or to factors associated with the use of the
Internet to deliver the treatment. No study to date has examined web-treatment of PTSD using
a well-established treatment program. An important unanswered question is whether moving from
the traditional, costly, access-limiting, therapist-delivered format of an effective
treatment to a more accessible, cost-effective, web-format will impact treatment efficacy. In
addition, based on evidence showing a link between neurosteroids and psychopathology and a
role in PTSD treatment response, an add-on biomarkers study was funded that examines the role
of candidate biomarkers [endogenous glucocorticoids and neurosteroids, i.e. cortisol,
allopregnanolone (ALLO) and metabolites, and dehydroepiandrosterone (DHEA/DHEAS)] as: a)
predictors of treatment response, and b) indices of therapeutic change during PTSD treatment.

Objective/Hypotheses: To eliminate the confound inherent in changing simultaneously both the
treatment program and the mode of delivery, the investigators propose to develop a
web-version of PE, "Web-PE", and compare its efficacy to Present Centered Treatment (PCT), an
active control comparison. The investigators hypothesize that Web-PE will be a more
efficacious in reducing PTSD severity than PCT among military personnel returned from
deployments in Afghanistan and Iraq at post-treatment and 3- and 6-months after treatment
completion. In addition, the investigators expect that changes cortisol and neurosteriods
will track symptom change.

Specific Aims: The first aim is to develop a Web-PE program that will receive high ratings of
ease of use, acceptability, comprehension of program content and functionality, and overall
satisfaction by military personnel with PTSD symptoms and an advisory board of eight experts
in PE and the treatment PTSD in the military. The second aim is to examine the efficacy of
Web-PE by comparing it to therapist-delivered PCT on the following outcomes: 1) Change in
PTSD severity and diagnostic status from pre- to post-treatment; 2) Change in symptoms of
depression, anger, and other frequently co-occurring problems from pre- to post-treatment.
The biological aims of the study include: 1) To identify specific neuroendocrine and
neurosteroid changes that "track" Posttraumatic Stress Disorder (PTSD) symptom change over
the course of effective treatment and 2) to determine the specificity of Prolonged Exposure
(PE) -induced neuroendocrine/neurosteroid changes by directly comparing patterns of change
during PE to those during Present Centered Therapy (PCT).

Study Design: During Phase I (months 0-9), the investigators will develop and demonstrate the
feasibility of the Web-PE program by piloting it with 10 military personnel with PTSD or
subclinical PTSD and by members of the expert advisory board. During Phase II (months 9-36),
the investigators will conduct an RCT comparing the efficacy of Web-PE with
therapist-delivered PCT on measures of PTSD symptom severity and related psychopathology with
160 OIF/OEF active duty military personnel with PTSD. Cortisol Awakening Response collected
at home on the three mornings prior to the research sessions that occur at baseline, week 4,
one and three months follow-up. Script driven imagery saliva collection for salivary cortisol
in response to the general environment and specific trauma cues at baseline, week 4, and one
and three months follow-up. Serum neurosteriods (allopregnanolone, pregnenolone,
pregnanolone, androsterone, DHEA) at baseline, week 4 and 1 month follow-up of treatment.

Relevance: Untreated PTSD becomes a chronic disorder, leaving military service-men and -women
less effective or unable to perform their military duties, more likely to have comorbid
mental and physical health problems as well as difficulties in daily functioning (Vasterling
et al., 2007). The proposed Web-PE program can function as the first step in a step care
model. As such it is expected to greatly facilitate the dissemination of EBT to those in need
by capitalizing on the greater accessibility, cost-effectiveness, and anonymity that is
afforded by Internet. Thus, the proposed study directly targets the MOM/JPC interest in
research aim at developing and validating novel EBTs that exploit innovative telemedicine
technologies. Because Web-PE could be accessed at home, the proposed study is also relevant
to the MOM/ JPC interest in strategies to reduce the stigma associated with PTSD treatment.
Integrating affective neuroscience methods into an RCT can make each study more informative,
effective, and less expensive than two independent studies. Neurobiological studies of PTSD
have linked specific candidate biomarkers [endogenous glucocorticoids and neurosteroids, i.e.
cortisol, allopregnanolone (ALLO) and metabolites, and dehydroepiandrosterone (DHEA/DHEAS)]
to PTSD severity and potentially to treatment response. Identifying the mechanisms involved
in treatment response can assist in improving therapeutic techniques by targeting specific
neurobiological processes involved.

This study is affiliated with the South Texas Research Organizational Network Guiding Studies
on Trauma and Resilience (STRONG STAR) (Consortium Director: Alan L. Peterson, Ph.D., ABPP,
Professor, Behavioral Wellness Center for Clinical Trials, Department of Psychiatry-Mail Code
7792, University of Texas Health Science Center at San Antonio (UTHSCSA), 7703 Floyd Curl
Drive, San Antonio, TX 78229-3900). The Overall PIs for this study are Carmen P. McLean,
Ph.D. of the Center for the Treatment and Study of Anxiety at the University of Pennsylvania
and, for the biological measures portion of the study, Sheila Rauch, Ph.D., ABPP of Emory
University. The PI for this study at the University of Texas Health Science Center at San
Antonio (UTHSCSA) is Alan Peterson, Ph.D., ABPP, Department of Psychiatry, Division of
Behavioral Medicine. The on-site PI is COL Jeffrey Yarvis, Ph.D.,Chief, Soldier Behavioral
Health/Outpatient Psychiatry, Carl R. Darnall Army Medical Center, 36000 Darnall Loop, Fort
Hood, TX, 76544. The study will be conducted at Fort Hood, Texas.

Inclusion Criteria:

- Adult male and female active duty military personnel or veterans who have deployment
since 9/11, ages 18-65 seeking treatment for PTSD. Veterans must be eligible for
military medical care on Fort Hood.

- Diagnosis of PTSD as determined by a Clinician Administered PTSD Scale for DSM-5
(CAPS-5) clinical interview score ≥ 25. Person has experienced a Criterion A event
that is a specific combat-related event or high magnitude operational experience that
occurred during a period of recent military deployment. The diagnosis of PTSD may be
indexed to that event or to another Criterion A event.

- Able to speak and read English

- Indication that the participant plans to be in the area for the next five months
following the first assessment

Exclusion Criteria:

- Recent manic episode (past 12 months) or a psychotic disorder (as determined by the
bipolar and psychosis sections of the MINI)

- Current alcohol dependence (as determined by an a score of ≥ 4 on items #4-6 and a
total score of ≥20 on the AUDIT)

- Evidence of a moderate or severe traumatic brain injury (as determined by the
inability to comprehend the baseline screening questionnaires)

- Current suicidal ideation severe enough to warrant immediate attention (as determined
by the Depressive Symptoms Index-Suicidality Subscale and corroborated by a clinical
risk assessment by a credentialed provider)

- Other psychiatric disorders severe enough to warrant designation as the primary
disorder

- Recent course of PE within the past 12 months

- Currently engaged in evidence-based treatment for PTSD (e.g. Prolonged Exposure
Therapy or Cognitive Processing Therapy